NanoPass Technologies Ltd., a Nes Ziona, Israel-based developer of painless intradermal (skin) delivery solutions for vaccines and large molecules, has recently closed a financing of undisclosed amount.
The round was led by Israel HealthCare Ventures (IHCV), with the participation of current investors including Ofer Hi-Tech, D-Partners, WFD Ventures and Elcam Medical.
The company intends to use the funding to accelerate market penetration of its applications through additional licenses with pharmaceutical companies.
Led by CEO Yotam Levin, MD, MBA, NanoPass is developing devices for intradermal delivery and cosmetic enhancement based on its Microneedles technology.
Its device MicronJet600 has an FDA registration and a CE Mark.
In conjunction with the financing, Dr Hadar Ron, Managing Partner of IHCV, has joined the company’s Board of Directors. In addition, Mr. Marvin Samson, founder and CEO of Samson Medical Technologies and Chairman of the Board of Trustees of the University of the Sciences, has been appointed as a Director.